Robert Neborsky
Psychiatry · del Mar, CANPI 1871610345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 336 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 25.4% of the total. Reporting peaked in 2019 at $1,987 and has fallen 66.7% since, to $661 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$997
- Otsuka America Pharmaceutical, Inc.$852
- Axsome Therapeutics, Inc.$805
- Johnson & Johnson$498
- plus $2K from 11 others
What the payments were for
- Speaking & faculty fees$6007%
- Food & beverage$7,40092%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 111 | $2,044 |
| Lundbeck LLC | 92 | $1,134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $997 |
| Otsuka America Pharmaceutical, Inc. | 26 | $852 |
| Axsome Therapeutics, Inc. | 18 | $805 |
| Johnson & Johnson | 16 | $498 |
| Eisai Inc. | 9 | $372 |
| Alkermes, Inc. | 4 | $263 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $203 |
| Bausch Health US, LLC | 9 | $195 |
| Idorsia Pharmaceuticals US Inc | 4 | $183 |
| Sunovion Pharmaceuticals Inc. | 11 | $173 |
| Vanda Pharmaceuticals Inc. | 7 | $167 |
| Astellas Pharma US Inc | 1 | $111 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$915
- VRAYLAR$872
- TRINTELLIX$600
- REXULTI$353
- Auvelity$347
- CAPLYTA$134
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- QUVIVIQ$118
- NONE$112
- Veozah$111
- Fycompa$100
How this compares
$8,044 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 68 | $81,810 |
| RexultiBrexpiprazole | 37 | $52,491 |
| VraylarCariprazine Hcl | 26 | $47,464 |
| TrintellixVortioxetine Hydrobromide | 76 | $46,623 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $9,144 |
| DayvigoLemborexant | 14 | $4,437 |
| Methylphenidate Hcl | 13 | $795 |
| Quetiapine Fumarate | 23 | $549 |
| Clonazepam | 48 | $511 |
| Vilazodone Hcl | 14 | $469 |
| Olanzapine | 12 | $364 |
| Lorazepam | 26 | $284 |
| Escitalopram Oxalate | 23 | $259 |
| Bupropion Hcl SrBupropion Hcl | 28 | $249 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $498 | $81,81068 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $997 | $55,76791 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $852 | $52,49137 claims |
| AbbVieVraylar | $2,044 | $47,46426 claims |
| Eisai Inc.Dayvigo | $372 | $4,43714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in del Mar
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.